Patent ID: 7767223
Filing Date: 2010-08-03
Classification: A61F,A61K,A61L,A61P

Abstract:
1. An intraocular, bioerodible drug delivery system comprising a steroid effective in preventing or reducing neovascularization in an eye prone to neovascularization, and a bioerodible polymer selected from the group consisting of hydroxyaliphatic carboxylic acids, and polysaccharides, thereby forming an implant for placement in the interior of an eye prone to neovascularization, wherein: (a) the steroid is dexamethasone and comprises about 50% to 80% of the weight of the drug delivery system; (b) the drug delivery system is configured for placement in the vitreous, wherein the system is effective in releasing the dexamethasone into the eye over a period of at least about 8 weeks.